Abstract：【Objective】 To investigate the efficacy of bikalumide in patients with advanced prostate cancer.【Methods】 A total of 92 patients with advanced prostate cancer admitted in our hospital from January 2016 to December 2017 were randomly divided into two groups, with 46 cases in each group. Patients in the control group received routine therapy with foserelin, while patients in the observation group was treated with bikalumide on the basis of foserelin routine treatment. The clinical efficacy and serum prostate specific antigen (PSA), vascular endothelial growth factor (VEGF), miRNA-34a (miR-34a), insulin-like growth factor-1 (IGF-1) levels and SMYD3 positive expression rate were compared before and after treatment. Quality of life measurement scale (QLQ-C30) score and patient satisfaction were evaluated as well.【Results】 The total effective rate of the observation group was 95.65% (44/46), which was significantly higher than that of the control group (80.43% (37/46)). The difference was statistically significant (P<0.05). There were no statistically significant differences between the two groups in the levels of PSA, VEGF, miR-34a,IGF-1, SMYD3 and QLQ-C30 before treatment (P>0.05). After treatment, the levels of PSA, VEGF, IGF- and SMYD3 in the observation group were lower than those in the control group, and the level of miR-34a and QLQ-C30 score were higher than those in the control group (P<0.05). The patient satisfaction in the observation group was 95.65%, which was significantly higher than that in the control group 54.35%, and the difference was statistically significant (P<0.05). 【Conclusion】 Bikalumide combined with goserelin have significant therapeutic effect in patients with advanced prostate cancer, which can reduce levels of PSA VEGF and IGF-1, increase miR-34a level, effectively control SMYD3 expression, improve the quality of life and enhance patient satisfaction.
陈翔, 王伟, 冉俊武, 刘杰, 卢启海. 比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌患者的疗效观察[J]. 医学临床研究, 2019, 36(1): 11-14.
CHEN Xiang, WANG Wei, RAN Jun-wu, et al. Effect of Bikalumide Combined with Goserelin in Patients with Advanced Prostate Cancer. JOURNAL OF CLINICAL RESEARCH, 2019, 36(1): 11-14.
2019, Vol. 36 
